Idera Pharmaceuticals Announces Upcoming Presentations of Data From Oncology Programs at Key Scientific Meetings

CAMBRIDGE, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for rare diseases, today announced the following data abstracts from its oncology programs were accepted for presentation at upcoming scientific meetings.

56th Annual Meeting of the American Society of Hematology
December 6-9, 2014; San Francisco, Calif.

IMO-8400, an Antagonist of Toll-like Receptors 7, 8, and 9, in Development for Genetically Defined B-Cell Lymphomas: Safety and Activity in Phase 1 and Phase 2 Clinical Trials
Session name: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II
Poster presentation time: Sunday, December 7, 2014, 6:00 - 8:00 p.m. PST
Abstract: #3101

Novel Approach to the Potential Treatment of Patients with B-Cell Lymphomas Harboring the MYD88 L265P Mutation: Combination Treatment with TLR Antagonist and Rituximab
Session name: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents I
Oral presentation time: Monday, December 8, 2014, 3:30 p.m. PST
Abstract: #508

American Association for Cancer Research Tumor Immunology and Immunotherapy Meeting
December 1-4, 2014; Orlando, Fla.

Intratumoral Injection of IMO-2055, a Novel Toll-like Receptor 9 Agonist, with Ipilimumab Induces a Systemic Tumor-specific Immune Response
Session name: Poster Session A
Poster presentation time: Tuesday, December 2, 1:15 - 3:30 p.m. EST

About Idera Pharmaceuticals

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare autoimmune diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit

CONTACT: Investor and Media Contact Jim Baker Executive Director, Corporate Affairs (617) 679-5516

Source:Idera Pharmaceuticals